Learn about chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and their symptoms. See full Prescribing & Safety Information.
Chronic lymphocytic leukemia, or CLL, is a slow-growing cancer of the blood and bone marrow. It is the most common type of adult leukemia.
Patients with low-risk (formerly Rai stage 0; Binet stage A) CLL, who have no evidence of disease progression or disease-related symptoms should be monitored without therapy. Similarly, most patients with intermediate-risk (formerly Rai stages I and II; Binet stage B) can be monitored without...
At this time, while treatment for CLL may be able to provide patients with symptom relief and control of their leukemia, it can not provide a cure, and the course of the disease is extremely variable between different people. However, our understanding of this unique type of leukemia is cons...
CALQUENCE® (acalabrutinib) is a BTK inhibitor indicated for the treatment of adult patients with R/R Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
View by Patient Type Contact a RepresentativeRegister for UpdatesPrescribing InformationSafety Information View Prescribing Information Choose a patient type: Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Acute Myeloid Leukemia (AML) ...
It’s not the main treatment for CLL, but you might get radiation to help treat some of the cancer’s symptoms. Radiation can: Shrink swollen organs, such as your spleen, that press on other organs and cause pain Ease pain from bone damage due to leukemia cells that grow in the bone ...
After a chronic lymphocytic leukemia (CLL) diagnosis, it’s normal to have questions. Thanks to your local library or your smartphone, you can do some research on your own, but nothing can take the place of talking to your doctor.
Learn about CALQUENCE® (acalabrutinib), a treatment option for adult patients with previously treated mantle cell lymphoma (R/R MCL) and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
's TFS and risk of death. Differentiating between CLL and MBL based on a patient's likelihood of developing clinical symptoms and dying of disease could minimize unnecessary psychologic distress caused by labeling asymptomatic individuals at low risk for adverse clinical consequences as having leukemia...